HomeUSAOmega Funds Promotes Francesco Draetta to Managing Director

Omega Funds Promotes Francesco Draetta to Managing Director

Omega Funds

Omega Funds, a Boston, MA-based international healthcare venture capital firm focused on delivering impactful medicines to patients, promoted Francesco Draetta to Managing Director.

Draetta joined the firm’s existing Managing Directors Claudio Nessi and Otello Stampacchia.

Draetta has led or co-led many of Omega’s investments, including Arcutis Biotherapeutics (IPO), Amunix Pharmaceuticals (acquired by Sanofi), Chord Therapeutics (acquired by Merck KGaA), and Lexeo Therapeutics (IPO), and was involved in the firm’s investment in Gossamer Bio (IPO), as well as several undisclosed direct secondary transactions. Draetta is currently on the board of directors for Beta Bionics, NRG Therapeutics, and one of Omega’s stealth company creations, where he also served as founding CEO, and is a board observer at ARTBIO. He also co-leads the Firm’s fundraising efforts, which resulted in more than $1.1 billion raised across Omega Fund VI and Omega Fund VII.

From 2008 to 2012, Draetta was an Analyst at Omega. Prior to rejoining Omega in 2016, he was part of the investment teams of Commonfund Capital and Brookside Mezzanine Partners. Francesco is a CFA charterholder, a CAIA charterholder, a FRM, and holds a BBA in Finance and Operations Management from the Isenberg School of Management at the University of Massachusetts Amherst.

Founded in 2004, Omega Funds is an international venture capital firm that creates and invests in life sciences companies that target our world’s most urgent medical needs. Omega focuses on supporting companies through value inflection points across the full arc of innovation, from formation through clinical and commercial milestones. Portfolio companies have brought 50 products to market in multiple therapeutic areas, including oncology, rare diseases, precision medicine and others.